| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
122,563,000 |
| Market
Cap: |
7.85(B) |
| Last
Volume: |
8,264,325 |
Avg
Vol: |
8,241,474 |
| 52
Week Range: |
$26.88 - $108.06 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Cytokinetics is a biopharmaceutical company focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. Co.'s clinical-stage drug candidates are: Omecamtiv mecarbil, which is being evaluated for the potential treatment of heart failure; Reldesemtiv, which is being evaluated for treatment in patients with amyotrophic lateral sclerosis; Aficamten, which is an oral, small molecule cardiac myosin inhibitor being evaluated in patients with symptomatic, obstructive hypertrophic cardiomyopathy; and CK-3772271, its second cardiac myosin inhibitor.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
93,271 |
236,512 |
412,985 |
896,841 |
| Total Sell Value |
$6,650,220 |
$16,321,203 |
$22,371,951 |
$44,047,420 |
| Total People Sold |
3 |
4 |
5 |
11 |
| Total Sell Transactions |
5 |
17 |
38 |
83 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Malik Fady Ibraham |
EVP Research & Development |
• • – |
2023-02-09 |
4 |
AS |
$43.73 |
$174,920 |
D/D |
(4,000) |
152,589 |
|
-18% |
|
| Wierenga Wendall D |
Director |
• • – |
2023-02-06 |
4 |
AS |
$45.00 |
$315,000 |
D/D |
(7,000) |
12,533 |
|
-21% |
|
| Wierenga Wendall D |
Director |
• • – |
2023-02-06 |
4 |
OE |
$6.72 |
$47,040 |
D/D |
7,000 |
19,533 |
|
- |
|
| Jaw Ching |
SVP Finance & CFO |
• • – |
2023-02-03 |
4 |
AS |
$45.00 |
$675,000 |
D/D |
(15,000) |
67,184 |
|
-22% |
|
| Jaw Ching |
SVP Finance & CFO |
• • – |
2023-02-03 |
4 |
OE |
$12.10 |
$181,500 |
D/D |
15,000 |
82,184 |
|
- |
|
| Wong Robert |
VP, Chief Accounting Officer |
• • – |
2023-02-03 |
4 |
AS |
$45.00 |
$135,180 |
D/D |
(3,004) |
27,533 |
|
-22% |
|
| Blum Robert I |
President & CEO |
• • – |
2023-01-17 |
4 |
AS |
$42.43 |
$424,300 |
D/D |
(10,000) |
406,412 |
|
-12% |
|
| Blum Robert I |
President & CEO |
• • – |
2023-01-17 |
4 |
OE |
$9.65 |
$96,500 |
D/D |
10,000 |
416,412 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• • – |
2023-01-12 |
4 |
AS |
$40.47 |
$161,880 |
D/D |
(4,000) |
156,589 |
|
-9% |
|
| Harrington Robert Arthur |
Director |
• • – |
2023-01-03 |
4 |
A |
$44.35 |
$11,221 |
D/D |
253 |
5,253 |
|
- |
|
| Wierenga Wendall D |
Director |
• • – |
2023-01-03 |
4 |
A |
$44.35 |
$11,221 |
D/D |
253 |
12,533 |
|
- |
|
| Smith Sandford D |
Director |
• • – |
2023-01-03 |
4 |
A |
$44.35 |
$11,221 |
D/D |
253 |
12,533 |
|
- |
|
| Wysenski Nancy |
Director |
• • – |
2023-01-03 |
4 |
A |
$44.35 |
$5,588 |
D/D |
126 |
11,522 |
|
- |
|
| Henderson John T |
Director |
• • – |
2023-01-03 |
4 |
A |
$44.35 |
$19,958 |
D/D |
450 |
24,890 |
|
- |
|
| Kaye Edward M. Md |
Director |
• • – |
2023-01-03 |
4 |
A |
$44.35 |
$11,221 |
D/D |
253 |
13,049 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2022-12-21 |
4 |
AS |
$43.92 |
$439,240 |
D/D |
(10,000) |
406,412 |
|
-13% |
|
| Blum Robert I |
President & CEO |
• • – |
2022-12-21 |
4 |
OE |
$9.65 |
$96,500 |
D/D |
10,000 |
416,412 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• • – |
2022-12-08 |
4 |
AS |
$36.28 |
$145,120 |
D/D |
(4,000) |
160,589 |
|
2% |
|
| Blum Robert I |
President & CEO |
• • – |
2022-12-05 |
4 |
AS |
$39.30 |
$392,970 |
D/D |
(10,000) |
406,412 |
|
-4% |
|
| Blum Robert I |
President & CEO |
• • – |
2022-12-05 |
4 |
OE |
$9.65 |
$96,500 |
D/D |
10,000 |
416,412 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2022-11-21 |
4 |
AS |
$40.89 |
$408,900 |
D/D |
(10,000) |
406,089 |
|
-9% |
|
| Blum Robert I |
President & CEO |
• • – |
2022-11-21 |
4 |
OE |
$9.65 |
$96,500 |
D/D |
10,000 |
416,089 |
|
- |
|
| Wong Robert |
VP, Chief Accounting Officer |
• • – |
2022-11-14 |
4 |
S |
$40.68 |
$85,428 |
D/D |
(2,100) |
30,537 |
|
12% |
|
| Malik Fady Ibraham |
EVP Research & Development |
• • – |
2022-11-10 |
4 |
AS |
$38.04 |
$152,160 |
D/D |
(4,000) |
164,346 |
|
-15% |
|
| Blum Robert I |
President & CEO |
• • – |
2022-11-02 |
4 |
AS |
$42.17 |
$421,700 |
D/D |
(10,000) |
406,089 |
|
-11% |
|
710 Records found
|
|
Page 7 of 29 |
|
|
1.25 (1.92%) 
